Mary Kay Inc. Partners With the Society of Investigative Dermatology (SID) to Award Educational Grants to Academic Research Fellows for Advancement in Research to Promote Skin Health
Mary Kay Inc., a global leader in skincare innovation, recently sponsored and revealed its inaugural Mary Kay Skin Health/Skin Disease Research Grants awardees for researchers conducting groundbreaking, innovative studies in skin health and skin disease at the 2022 Society for Investigative Dermatology (SID) Annual Meeting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005229/en/
Dr. Lucy Gildea, Ph.D., Mary Kay Chief Innovation Officer, Product and Science (Photo: Mary Kay Inc.)
“As a decades-long leader in global cosmetics and skincare innovation, Mary Kay remains committed to enriching women’s lives across the world,” said Dr. Lucy Gildea, Mary Kay’s Chief Innovation Officer, Product and Science, at the event. “We also have a steadfast commitment to producing the highest quality products and conducting breakthrough skin science research. We recognize collaboration is crucial to new discoveries, and partnerships with scientific, medical, and academic communities are vital collaborations—which is why we’re thrilled to award these scientific grants.”
The Mary Kay Skin Health/Skin Disease Research Grants were announced at last year’s meeting in partnership with SID. The $25,000 grants were to be awarded to four researchers conducting incredible work in skin research to uncover new perspectives and invention strategies. In the months following the 2021 SID meeting, the company received applications from scientists across the country.
The four grant awardees ultimately selected were:
- Dr. Allison C. Billi, MD, Ph.D., and Assistant Professor in the Dept of Dermatology at the University of Michigan. Dr. Billi’s primary research goal is to understand “what drives photoaging.” The grant will fund research to identify targetable pathways that help prevent or potentially reverse the effects of photoaging.
- Dr. Angel S. Byrd, MD, Ph.D. and Assistant Professor at Howard University College of Medicine and Adjunct Assistant Professor at JHUSOM (Departments of Dermatology). Dr. Byrd’s work focuses on the genetic basis of melasma. This grant will fund research to help discover unknown genetic causes of melasma to design personalized treatment options.
- Dr. Mae Alexandra Carpenter, Ph.D. Trainee at Wright State University. Dr. Carpenter’s work explores how damaged DNA-containing particles are released and how they activate inflammatory pathways. Funding this research will help develop new therapeutic approaches to reduce UVB photosensitivity in autoinflammatory diseases.
- Dr. Jennifer Powers, MD and Clinical Associate Professor in the Dept of Dermatology at the University of Iowa. Dr. Powers is interested in the influence of the microbiome and the healing environment on wound healing and scar formation. Funding for this research will help understand how the immune system and microbiota interact to modify scar formation from ulcers and surgical wounds.
“Congratulations to each of our 2022 grant award recipients,” added Dr. Gildea. “These individuals were carefully chosen in collaboration with the Society for Investigative Dermatology—and we are thrilled to support their research.”
The sponsorship and grants revealed at SID are just the latest efforts by Mary Kay to reinforce the company’s long-standing commitment to advancing skin health research and development. Mary Kay holds more than 1,600 patents for products, technologies, and packaging designs in its global portfolio.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005229/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 202522.9.2025 21:30:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present new data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. The data, which will be presented in a late-breaking oral presentation on Sunday, October 19, 2025, focuses on trial participants who were previously treated with a PARP inhibitor, a patient population with particularly poor prognosis. The ROSELLA trial is being conducted in collaboration with The GOG Foundation, Inc. (GOG-F), the European Network of Gynaecological Oncological Trial groups (ENGOT), the Asia-Pacific Gynecologic Oncology Trials Group (APGOT), the Latin American Cooperative Oncology Group (LACOG) a
Vantiva’s Cobra 5G Router Earns T-Mobile Certification, Expanding 5G Access for MVNO Ecosystems22.9.2025 19:00:00 EEST | Press release
Vantiva (Euronext Paris: VANTI), a global technology leader in connectivity, today announced that T-Mobile has officially certified Vantiva’s Cobra 5G Fixed Wireless Access (FWA) router for deployment within its Mobile Virtual Network Operator (MVNO) ecosystem. This certification expands opportunities for T-Mobile MVNOs to access advanced 5G FWA technology. With this certification, MVNOs operating on T-Mobile’s network, the largest 5G network in America, can now offer the Cobra 5G router directly to their clients. Vantiva’s Cobra 5G delivers high-performance connectivity with features specifically designed to meet businesses' operational needs. Key features of the product and ecosystem include: WAN Sensing™ to ensure uninterrupted connectivity with seamless network switching from a primary to backup connection Indoor5G™ and RuralBoost™ technologies to enable Cobra 5G to extend the FWA service area by up to 40% via proven proprietary technologies NaviGate Companion™ mobile application f
Arada Enters UK with Acquisition of British Developer Regal, Committing AED2.5 Billion to Accelerate London Residential Development22.9.2025 17:31:00 EEST | Press release
Arada has announced its expansion into the UK housing market through the acquisition of a 75% stake in Regal, one of London’s leading residential-led mixed-use developers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250922005640/en/ Arada enters UK with acquisition of British developer Regal, committing AED2.5 billion to accelerate London residential development (Photo: AETOSWire) This marks Arada’s entry into the UK and second international expansion, aligning with its strategy of growing and diversifying its business geographically. Having already established a strong presence in the UAE since its launch in 2017 and expanded into Australia in 2024, the acquisition of Regal gives Arada an immediate presence in the London market and platform on which to deliver at speed and scale. As part of the transaction, Arada is also committing an initial AED2.5 billion of capital to acquire and invest in the 150-person-strong Regal
Onego Bio Receives FDA “No Questions” Letter on GRAS Status of Bioalbumen®22.9.2025 17:00:00 EEST | Press release
Onego Bio, a food ingredient company producing egg protein through precision fermentation, announced today that the U.S. Food and Drug Administration (FDA) has issued a “no questions” letter regarding the company’s conclusion that its flagship product, marketed as Bioalbumen®, is Generally Recognized As Safe (GRAS) under its conditions of use in a wide range of food and beverage applications. The FDA’s decision, communicated in response to GRAS Notice No. GRN 1249, confirms that Bioalbumen®—a highly functional ovalbumin protein with an amino acid sequence identical to that found in chicken eggs—can be used as a source of dietary protein and, for example, as a foaming, gelling, and binding agent in baked goods, beverages, meat analogs, confections, sauces, and more. Produced via precision fermentation with the filamentous fungus Trichoderma reesei, Bioalbumen® delivers high-quality nutrition and matches the functionality of traditional egg protein. It is designed to diversify egg protei
Boomi Appoints Keyur Ajmera as Chief Information Officer22.9.2025 16:00:00 EEST | Press release
Boomi™, the leader in AI-driven automation, today announced the appointment of Keyur Ajmera as Chief Information Officer, responsible for driving Boomi’s global IT strategy, enterprise systems, cybersecurity, and digital operations. Ajmera will focus on scaling technology to support Boomi’s rapid growth, strengthening the company’s IT foundation for AI adoption, and ensuring operational excellence as Boomi accelerates its agentic transformation journey. He will report to President of Global Operations and Chief Financial Officer, Val Rainey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250922974855/en/ Boomi Appoints Keyur Ajmera as Chief Information Officer Ajmera, who most recently served as Senior Vice President of Technology Operations and Innovation at Towne Park and previously as the first CIO of iCIMS, brings more than two decades of experience in enterprise IT leadership, digital transformation, and product operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom